Journal
VACCINE
Volume 26, Issue 51, Pages 6671-6677Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.09.016
Keywords
HIV preventive vaccine; Clinical trial; PTHr.HIVA DNA; MVA.HIVA
Categories
Funding
- International AIDS Vaccine Initiative
- Medical Research Council [G0502048, G0600007, G0501957, MC_U122861400, MC_U137884177, MC_U137884179] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0507-10313] Funding Source: researchfish
- MRC [MC_U137884179, MC_U137884177, G0600007, MC_U122861400, G0502048, G0501957] Funding Source: UKRI
Ask authors/readers for more resources
IAVI-006 was the first large randomised, double-blinded, placebo-controlled Phase I clinical trial to systematically investigate the prime-boost strategy for induction of HIV-1 specific CD8+ cytotoxic T-lymphocytes (CTL) in a factorial trial design using (i) priming with 0.5 mg or 2 mg of pTHr.HIVA DNA vaccine, followed by (ii) two booster vaccinations with 5 x 10(7) MVA.HIVA at weeks 8 and 12 (early boost) or weeks 20 and 24 (late boost). This Study set the basis for later clinical trials and dernonstrated the safety of these candidate HIV vaccines. The safety and immunogenicity results are presented and the lessons derived from this clinical trial are discussed. (C) 2008 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available